CytoSorbents Corp stock (US23283M1018): analyst sentiment and low share price keep focus on Nasdaq-listed medtech

CytoSorbents Corp shares on Nasdaq remain near the lower end of their recent trading range, while a small group of Wall Street analysts continues to publish 12-month price targets for the United States-based medtech company.

CytoSorbents Corp shares traded at USD 0.49 on 05/29/2026 on the Nasdaq Capital Market under the ticker CTSO, according to MarketBeat as of 05/29/2026, leaving the United States-listed stock at a low nominal level despite ongoing coverage from several Wall Street research houses.MarketBeat as of 05/29/2026

The New Jersey-based medical technology player, whose primary listing is in the United States, continues to draw attention because consensus 12-month price objectives from analysts remain well above the current market price, even as the shares closed unchanged at USD 0.49 on 05/29/2026 on Nasdaq.MarketBeat forecast page as of 05/29/2026

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: CytoSorbents Corp
• Sector/industry: Medical technology / blood purification devices
• Headquarters/country: Princeton, United States
• Core markets: Intensive care and cardiac surgery settings in North America and Europe
• Key revenue drivers: Hemoadsorption cartridges and related blood purification products for critical care
• Home exchange/listing venue: Nasdaq Capital Market (CTSO)
• Trading currency: USD

CytoSorbents Corp: core business model

CytoSorbents Corp focuses on blood purification therapies for critically ill patients, generating its revenue primarily from selling hemoadsorption cartridges and related medical devices to hospitals and clinics in intensive care and cardiac surgery.

What banks and research houses say about CytoSorbents Corp

For CytoSorbents on Nasdaq, aggregated analyst data indicate that three Wall Street equity research analysts currently follow the stock, with a consensus 12-month price target of USD 5.38 as of 05/29/2026, compared with the closing price of USD 0.49 on the same date, according to MarketBeat.MarketBeat forecast page as of 05/29/2026

The same MarketBeat data as of 05/29/2026 show that the high individual target among these analysts stands at USD 10.00, while the lowest is USD 0.75, and the consensus rating is described as "hold," underscoring that the small analyst group is not signaling a clear directional call even though the average target sits materially above the latest Nasdaq trading level.MarketBeat forecast page as of 05/29/2026

Conclusion

With CytoSorbents Corp trading at USD 0.49 on Nasdaq on 05/29/2026 and remaining focused on blood purification devices for critical care, the United States medtech name stays in the spotlight because its analyst-derived price targets cluster well above the current level.

The modest number of covering research houses, a consensus "hold" stance, and a wide range between the highest and lowest target underline the ongoing uncertainty around the companys execution path and financial profile even as the Nasdaq listing keeps it visible to international investors.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.